Minimal Important Difference (MID) of the Dermatology Life Quality Index (DLQI): Results from Patients with Chronic Idiopathic Urticaria

Overview

Journal Health Qual Life Outcomes

Publisher Biomed Central

Specialty Public Health

Date 2005 May 24

PMID 15907211

Citations 26

Authors

Richard Shikiar

Gale Harding

Michael Leahy

Richard D Lennox

Affiliations

Soon will be listed here.

Abstract

Background: The Dermatology Quality Life Index (DLQI) has seen widespread use as a health-related quality of life measure for a variety of dermatological diseases. The purpose of this study was to estimate the minimal important difference (MID) on the DLQI for patients with chronic idiopathic urticaria (CIU).

Methods: Data from 2 Phase III clinical trials of patients (N = 476 for Study A; N = 468 for Study B) with CIU were analyzed separately to estimate the MID for the DLQI for these populations. Both distributional based and anchor based approaches were used for deriving estimates. The anchor based approach relied upon patient self assessments of pruritus severity; the distributional based approaches relied upon estimating the standard error of measurement, as well as one-half the standard deviation of the DLQI from each study.

Results: The distributional approaches resulted in estimates of MID ranging from 2.24 to 3.10 for the two studies. The anchor based approach resulted in estimates of 3.21 and 2.97 for the two studies.

Conclusion: An MID for the DLQI in the range of 2.24 to 3.10 is recommended in interpreting results for patients with CIU.

Citing Articles

Minimal clinically important difference for acupuncture for patients with chronic spontaneous urticaria: secondary analysis from a multicentre randomised controlled trial in China.

Xiao X, Cao W, Zou Z, Chen S, Yang Q, Qin D BMJ Open. 2024; 14(10):e085041.

PMID: 39477260 PMC: 11529762. DOI: 10.1136/bmjopen-2024-085041.

Exploring cognitive reserve's influence: unveiling the dynamics of digital telerehabilitation in Parkinson's Disease Resilience.

Isernia S, Di Tella S, Rossetto F, Borgnis F, Realdon O, Cabinio M NPJ Digit Med. 2024; 7(1):116.

PMID: 38710915 PMC: 11074106. DOI: 10.1038/s41746-024-01113-9.

Sensitivity to change and minimal clinically important difference of the angioedema control test.

Fijen L, Vera C, Buttgereit T, Bonnekoh H, Maurer M, Magerl M Clin Transl Allergy. 2023; 13(9):e12295.

PMID: 37746798 PMC: 10472988. DOI: 10.1002/clt2.12295.

Protocol for a feasibility trial (EXPRESS-C-GVHD) for an expressive helping intervention within a support group for cutaneous graft-versus-host-disease.

Kaundinya T, Kye Y, El-Behaedi S, Choi J Arch Dermatol Res. 2023; 315(10):2905-2912.

PMID: 37698591 DOI: 10.1007/s00403-023-02718-y.

Female Pattern Hair Loss and Negative Psychological Impact: Possible Role of Brain-derived Neurotrophic Factor (BDNF).

Mohamed N, Soltan M, Galal S, El Sayed H, Hassan H, Khatery B Dermatol Pract Concept. 2023; 13(3).

PMID: 37557155 PMC: 10412050. DOI: 10.5826/dpc.1303a139.

References

Ginsburg I, Link B . Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol. 1989; 20(1):53-63. DOI: 10.1016/s0190-9622(89)70007-4. View

Norman G, Sloan J, Wyrwich K . Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003; 41(5):582-92. DOI: 10.1097/01.MLR.0000062554.74615.4C. View

Touw C, Hakkaart-van Roijen L, Verboom P, Paul C, Rutten F, Finlay A . Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol. 2001; 144(5):967-72. DOI: 10.1046/j.1365-2133.2001.04183.x. View

Nelson H, Reynolds R, Mason J . Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2000; 84(5):517-22. DOI: 10.1016/S1081-1206(10)62515-X. View

Finn Jr A, Kaplan A, Fretwell R, Qu R, Long J . A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999; 104(5):1071-8. DOI: 10.1016/s0091-6749(99)70091-6. View

Shikiar R, Bresnahan B, Stone S, Thompson C, Koo J, Revicki D . Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes. 2003; 1:53. PMC: 269993. DOI: 10.1186/1477-7525-1-53. View

Wyrwich K, Tierney W, Wolinsky F . Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999; 52(9):861-73. DOI: 10.1016/s0895-4356(99)00071-2. View

Wyrwich K, Nienaber N, Tierney W, Wolinsky F . Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care. 1999; 37(5):469-78. DOI: 10.1097/00005650-199905000-00006. View

Grosshans E, Marks R, Mascaro J, Torras H, Meynadier J, Alirezai M . Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol. 1999; 139 Suppl 52:26-33. DOI: 10.1046/j.1365-2133.1998.1390s2026.x. View

10.

Juniper E . Quality of life questionnaires: does statistically significant = clinically important?. J Allergy Clin Immunol. 1998; 102(1):16-7. DOI: 10.1016/s0091-6749(98)70048-x. View

11.

Guyatt G, Jaeschke R . Reassessing quality-of-life instruments in the evaluation of new drugs. Pharmacoeconomics. 1997; 12(6):621-6. DOI: 10.2165/00019053-199712060-00002. View

12.

McHorney C, TARLOV A . Individual-patient monitoring in clinical practice: are available health status surveys adequate?. Qual Life Res. 1995; 4(4):293-307. DOI: 10.1007/BF01593882. View

13.

Finlay A, Coles E . The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol. 1995; 132(2):236-44. DOI: 10.1111/j.1365-2133.1995.tb05019.x. View

14.

Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

15.

Juniper E, Guyatt G, Willan A, Griffith L . Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994; 47(1):81-7. DOI: 10.1016/0895-4356(94)90036-1. View

16.

Ryan T . Disability in dermatology. Br J Hosp Med. 1991; 46(1):33-6. View

17.

Jowett S, Ryan T . Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med. 1985; 20(4):425-9. DOI: 10.1016/0277-9536(85)90021-8. View

18.

Cella D, Hahn E, Dineen K . Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002; 11(3):207-21. DOI: 10.1023/a:1015276414526. View